Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Our objective was to define the prevalence and clinical features of genetic Parkinson’s disease in a large UK population-based cohort, the largest multicentre prospective clinico-genetic incident study in the world. We collected demographic data, Movement Disorder Society Unified Parkinson’s Disease Rating Scale scores, and Montreal Cognitive Assessment scores. We analysed mutations in PRKN (parkin), PINK1, LRRK2 and SNCA in relation to age at symptom onset, family history and clinical features. Of the 2262 participants recruited to the Tracking Parkinson’s study, 424 had young-onset Parkinson’s disease (age at onset ≤ 50) and 1799 had late onset Parkinson’s disease. A range of methods were used to genotype 2005 patients: 302 young-onset patients were fully genotyped with multiplex ligation-dependent probe amplification and either Sanger and/or exome sequencing; and 1701 late-onset patients were genotyped with the LRRK2 ‘Kompetitive’ allele-specific polymerase chain reaction assay and/or exome sequencing (two patients had missing age at onset). We identified 29 (1.4%) patients carrying pathogenic mutations. Eighteen patients carried the G2019S or R1441C mutations in LRRK2, and one patient carried a heterozygous duplication in SNCA. In PRKN, we identified patients carrying deletions of exons 1, 4 and 5, and P113Xfs, R275W, G430D and R33X. In PINK1, two patients carried deletions in exon 1 and 5, and the W90Xfs point mutation. Eighteen per cent of patients with age at onset ≤30 and 7.4% of patients from large dominant families carried pathogenic Mendelian gene mutations. Of all young-onset patients, 10 (3.3%) carried biallelic mutations in PRKN or PINK1. Across the whole cohort, 18 patients (0.9%) carried pathogenic LRRK2 mutations and one (0.05%) carried an SNCA duplication. There is a significant burden of LRRK2 G2019S in patients with both apparently sporadic and familial disease. In young-onset patients, dominant and recessive mutations were equally common. There were no differences in clinical features between LRRK2 carriers and non-carriers. However, we did find that PRKN and PINK1 mutation carriers have distinctive clinical features compared to young-onset non-carriers, with more postural symptoms at diagnosis and less cognitive impairment, after adjusting for age and disease duration. This supports the idea that there is a distinct clinical profile of PRKN and PINK1-related Parkinson’s disease. We estimate that there are approaching 1000 patients with a known genetic aetiology in the UK Parkinson’s disease population. A small but significant number of patients carry causal variants in LRRK2, SNCA, PRKN and PINK1 that could potentially be targeted by new therapies, such as LRRK2 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Next-generation genotype imputation service and methods
Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A., Vrieze, S. I., Chew, E. Y., Levy, S., McGue, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3656 · Cited by 3,808 · cited 1×
“For imputation, genotypes were aligned to the 1000 Genomes Phase 3 v5 mixed population reference panel (Auton et al. , 2015) (build hg19/ GRCh37) and imputed using Minimac3 (Das et al. , 2016) on the Michigan Imputation Server (Supplementary material).”
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
A common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
Self-citationGenetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457
Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448 · cited 2×
“SNCA triplications cause a more severe phenotype while duplications tend to cause more ‘typical’ Parkinson’s disease (Chartier-Harlin et al., 2004; Ibáñez et al., 2004; Hernandez et al., 2016).”
BackgroundMethod
Cited by
Li, L., Acioglu, C., Heary, R. F., & Elkabes, S. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.007 · Cited by 283
Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study
Cook, L., Verbrugge, J., Schwantes-An, T.-H., Schulze, J., Foroud, T., Hall, A., Marder, K. S., Mata, I. F., Mencacci, N. E., Nance, M. A., et al. (2024) · Brain · doi:10.1093/brain/awae142 · Cited by 108
“8,9 The c.6055G > A (p.Gly2019Ser) variant was the predominant abnormal finding in LRRK2 , similar to reports of Parkinson’s disease genetic testing results in other European-based b A s h k e n a z i J e w i s h , S p a n i s h B a s q u e , N o r t h A f r i c a n B e r b e r .”
ResultA mutational atlas for Parkin proteostasis
Clausen, L., Voutsinos, V., Cagiada, M., Johansson, K. E., Grønbæk-Thygesen, M., Nariya, S., Powell, R. L., Have, M. K. N., Oestergaard, V. H., Stein, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45829-4 · Cited by 51
Emerging roles of leptin in Parkinson’s disease: Chronic inflammation, neuroprotection and more?
Regensburger, M., Rasul Chaudhry, S., Yasin, H., Zhao, Y., Stadlbauer, A., Buchfelder, M., & Kinfe, T. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.09.010 · Cited by 17
A substrate-interacting region of Parkin directs ubiquitination of the mitochondrial GTPase Miro1
Koszela, J., Rintala-Dempsey, A., Salzano, G., Pimenta, V., Kamarainen, O., Gabrielsen, M., Parui, A. L., Shaw, G. S., & Walden, H. (2025) · Journal of Cell Biology · doi:10.1083/jcb.202408025 · Cited by 13
Metadata
- Authors
- Tan, M. M. X., Malek, N., Lawton, M. A., Hubbard, L., Pittman, A. M., Joseph, T., Hehir, J., Swallow, D. M. A., Grosset, K. A., Marrinan, S. L., Bajaj, N., Barker, R. A., Burn, D. J., Bresner, C., Foltynie, T., Hardy, J., Wood, N., Ben-Shlomo, Y., Grosset, D. G., Williams, N. M., & Morris, H. R.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-19
- Volume
- 142
- Issue
- 9
- Pages
- 2828-2844
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2941638496
- Cited by
- 81
- References
- 5
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study. https://app.cochat.ai/papers/10.1093/brain/awz191
- The paper
- Tan, M. M. X., Malek, N., Lawton, M. A., Hubbard, L., Pittman, A. M., Joseph, T., Hehir, J., Swallow, D. M. A., Grosset, K. A., Marrinan, S. L., Bajaj, N., Barker, R. A., Burn, D. J., Bresner, C., Foltynie, T., Hardy, J., Wood, N., Ben-Shlomo, Y., Grosset, D. G., . . . Morris, H. R. (2019). Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study. Brain. https://doi.org/10.1093/brain/awz191
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.